Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci

Nikolaos A. Patsopoulos, Bayer Pharma MS Genetics Working Group, Steering Committees of Studies Evaluating IFNβ‐1b and a CCR1‐Antagonist, ANZgene, GeneMSA, International Multiple Sclerosis Genetics Consortium, Federica Esposito, Joachim Reischl, Stephan Lehr, David Bauer, Jürgen Heubach, Rupert Sandbrink, Christoph Pohl, Gilles Edan, Ludwig Kappos, David Miller, Javier Montalbán, Chris H. Polman, Mark S. Freedman, Hans Peter HartungBarry G.W. Arnason, Giancarlo Comi, Stuart Cook, Massimo Filippi, Douglas S. Goodin, Douglas Jeffery, Paul O'Connor, George C. Ebers, Dawn Langdon, Anthony T. Reder, Anthony Traboulsee, Frauke Zipp, Sebastian Schimrigk, Jan Hillert, Melanie Bahlo, David R. Booth, Simon Broadley, Matthew A. Brown, Brian L. Browning, Sharon R. Browning, Helmut Butzkueven, William M. Carroll, Caron Chapman, Simon J. Foote, Lyn Griffiths, Allan G. Kermode, Trevor J. Kilpatrick, Jeanette Lechner-Scott, Mark Marriott, Deborah Mason, Pablo Moscato, Robert N. Heard, Michael P. Pender, Victoria M. Perreau, Devindri Perera, Justin P. Rubio, Rodney J. Scott, Mark Slee, Jim Stankovich, Graeme J. Stewart, Bruce V. Taylor, Niall Tubridy, Ernest Willoughby, James Wiley, Paul Matthews, Filippo M. Boneschi, Alastair Compston, Jonathan Haines, Stephen L. Hauser, Jacob McCauley, Adrian Ivinson, Jorge R. Oksenberg, Margaret Pericak-Vance, Stephen J. Sawcer, Philip L. De Jager, David A. Hafler, Paul I.W. de BakkerShow 57 moreShow less